Open Orphan plc Signs Additional Laboratory Services Contracts
July 07, 2020 at 02:00 am EDT
Share
Open Orphan plc announced that as part of opening up its hVIVO laboratory services to third parties that it has signed 3 new contracts with third parties; NoBACZ Ltd. who are a spin-out company of the University of Cambridge, a new second contract with Nearmedic International Ltd. and a contract to run in-vitro testing from its laboratory for a Cambridge, Massachusetts biotech. NoBACZ Ltd. is developing an environmentally friendly antimicrobial, antiviral coating that prevents common-touch surfaces from being a major source of infection transmission during and beyond the COVID-19 outbreak. The innovative, customisable antimicrobial coating has a multitude of applications across public spaces and industries. Applied as a liquid, the NoBACZ product is adhesive and water repellent and sets into a solid but flexible barrier that is robust enough to form a semi-permanent coating on a wide variety of surfaces. The product's composition can be fine-tuned to produce a thin or thick coating to suit different surfaces and materials, with the ability to adapt the product's life-span before it naturally degrades such that there is no need to manually remove it. NoBACZ Ltd. is working with hVIVO, at its laboratory in East London, to test its products against a range of viruses, including coronaviruses and ultimately, against SARS-CoV-2, the virus strain that causes COVID-19 disease. If successful, the long-lasting coating can be applied to high-touch surfaces in public transport, office buildings, hospitals, gyms, care-homes, and supermarkets. hVIVO has also recently signed a contract to run in vitro testing from its laboratory for a Cambridge, Massachusetts based biotech company. In addition, hVIVO had also signed another contract with Nearmedic International Ltd, the Company's second in recent times, to support the development of a RegG3 drug as a treatment for COVID-19 followed by the expansion of this product into several disease areas such as Cystic Fibrosis.
hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.
HVIVO PLC 
